AI Article Synopsis
- The study aimed to assess the safety and long-term effectiveness of drug-eluting stents (DES) compared to bare-metal stents (BMS) in a rabbit model using frequency-domain optical coherence tomography (FD-OCT).
- Thirteen rabbits had a zotarolimus-eluting stent implanted in one iliac vein (DES Group) and a bare-metal stent in the opposite vein (BMS Group), achieving a 100% technical success rate.
- Results showed no significant difference in neointimal hyperplasia between the two groups after three months, indicating that DES use in the venous system is both safe and effective.
Article Abstract
Introduction: This protocol was designed to evaluate the safety and feasibility of implanting drug-eluting stents (DES), as well as to compare their long-term results versus bare-metal stents (BMS), in a rabbit venous model, using frequency-domain optical coherence tomography (FD-OCT).
Methods: Thirteen New Zealand white rabbits underwent implantation of a zotarolimus-eluting stent in the iliac vein (DES Group) and a BMS in the contralateral iliac vein (BMS Group). The study's primary endpoints included technical success and the comparison of in-stent neointimal hyperplasia in the two study groups, using ex vivo FD-OCT, at 3 months.
Results: Thirteen DES and 13 BMS were successfully implanted. The technical success rate was 100% (26/26 stents). Three animals (3/13, 23.0%) died within the first 45 days. The remaining 10/13 animals (77%) were euthanized on the 90th day following stent implantation. The 20 stents were successfully removed. Successful ex vivo FD-OCT was performed in all stent-implanted iliac vein segments, 10 in the DES Group and 10 in the BMS Group. There was no statistically significant difference in the mean neointimal thickness between the two groups (3.02 ± 1.19 mm2 in DES Group vs. 2.76 ± 1.17 mm2 in BMS Group; p=0.0501).
Conclusions: In this experimental protocol, DES implantation in the venous system was safe and feasible. Hyperplasia thickness was similar in both groups after 3 months' follow up.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-label ARIVA Trial.
Circulation
January 2025
Department of Angiology, University Hospital Zurich, University of Zurich, Switzerland.
Background: In patients with post-thrombotic syndrome (PTS), stent recanalization of iliofemoral veins or the inferior vena cava can restore venous patency and improve functional outcomes. The risk of stent thrombosis is particularly increased during the first 6 months after intervention. The ARIVA trial tested whether daily aspirin 100 mg plus rivaroxaban 20 mg is superior to rivaroxaban 20 mg alone to prevent stent thrombosis within 6 months after stent placement for PTS.
View Article and Find Full Text PDFEndovascular Approaches to Diagnosing Pelvic Varicose Veins in Men: Investigating Efficacy and Outcomes.
Surg Technol Int
January 2025
Department of Psychiatry and Narcology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.
Pelvic Venous Disorder (PEVD) and May-Thurner syndrome (MTS) represent relatively understudied vascular issues that can significantly impact patients' quality of life. This study aims to evaluate the efficacy of surgical treatment for PEVD and MTS, conduct a comparative analysis of outcomes, and determine the practical significance of different therapeutic approaches. The study was conducted from 2019 to 2022 in Moscow, Russia, encompassing two outpatient clinics.
View Article and Find Full Text PDFPurpose: To explore the anatomical features of left iliac vein (LIV) in non-thrombotic venous leg ulcers (VLUs) and to identify the impact of these anatomical features on VLUs based on computed tomography venography (CTV).
Methods: This is a retrospective, single-center study of a database (2021-2023) of 431 patients with non-thrombotic chronic venous insufficiency. According to CEAP clinical (C) classifications, cases of C6 and C2 were included for analysis as case and control groups.
Purpose: To evaluate longer term outcomes of the Zilver Vena Venous Stent in patients undergoing venous stenting.
Materials And Methods: Patients with iliofemoral obstructive venous disease and treated with venous stents were retrospectively enrolled in a physician-led real-world data collection effort. Results were analyzed by etiologies: post-thrombotic syndrome (PTS), non-thrombotic iliac vein lesion (NIVL), and iliocaval acute deep vein thrombosis (aDVT).
"May-Thurner syndrome as an underlying cause of unilateral left-sided deep vein thrombosis in a young healthy female: A case report".
Radiol Case Rep
March 2025
Department of Radiology, Rafidia Surgical Hospital, Nablus, Palestine.
May-Thurner syndrome (MTS), iliac vein compression syndrome, also called Cockett syndrome, is a vascular disease caused by the compression of the left common iliac vein (LCIV) by the right common iliac artery (RCIA) against the lumbar vertebrae. This anatomical defect can lead to venous stasis especially in the left lower limb, and this increases the risk of deep venous thrombosis (DVT). Because routine screening is not standard practice, MTS frequently remains asymptomatic, and its prevalence is probably underestimated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!